LRRK2 and Parkinsonism: The fact that we could rescue G2019S-impared mitophagy in PD-relevant cell types, within the brain, provides an exciting prospect that LRRK2 inhibitor-mediated correction of mitophagic defects in Parkinson’s patients could have therapeutic utility in the clinic.